Maqola

Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells

Wanjuan YangCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UKJorge SoaresMassachusetts General HospitalPatricia GreningerMassachusetts General HospitalElena J. EdelmanCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK, 2Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA, 3Core Software Services, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK and 4Howard Hughes Medical Institute, Chevy Chase, MD 20815, USAHoward LightfootHoward Hughes Medical Institute, Chevy Chase, United StatesSimon ForbesHoward Hughes Medical Institute, Chevy Chase, United StatesNidhi BindalHoward Hughes Medical Institute, Chevy Chase, United StatesDave BeareMassachusetts General HospitalJames SmithCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK, 2Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA, 3Core Software Services, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK and 4Howard Hughes Medical Institute, Chevy Chase, MD 20815, USAI. Richard ThompsonCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK, 2Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA, 3Core Software Services, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK and 4Howard Hughes Medical Institute, Chevy Chase, MD 20815, USASridhar RamaswamyCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK, 2Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA, 3Core Software Services, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK and 4Howard Hughes Medical Institute, Chevy Chase, MD 20815, USAP. Andrew FutrealCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK, 2Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA, 3Core Software Services, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK and 4Howard Hughes Medical Institute, Chevy Chase, MD 20815, USADaniel A. HaberHoward Hughes Medical Institute, Chevy Chase, United StatesMichael R. StrattonCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK, 2Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA, 3Core Software Services, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK and 4Howard Hughes Medical Institute, Chevy Chase, MD 20815, USACyril H. BenesHoward Hughes Medical Institute, Chevy Chase, United StatesUltan McDermottHoward Hughes Medical Institute, Chevy Chase, United StatesMathew J. GarnettMassachusetts General Hospital

2012en

ABI

Annotatsiya

Alterations in cancer genomes strongly influence clinical responses to treatment and in many instances are potent biomarkers for response to drugs. The Genomics of Drug Sensitivity in Cancer (GDSC) database (www.cancerRxgene.org) is the largest public resource for information on drug sensitivity in cancer cells and molecular markers of drug response. Data are freely available without restriction. GDSC currently contains drug sensitivity data for almost 75 000 experiments, describing response to 138 anticancer drugs across almost 700 cancer cell lines. To identify molecular markers of drug response, cell line drug sensitivity data are integrated with large genomic datasets obtained from the Catalogue of Somatic Mutations in Cancer database, including information on somatic mutations in cancer genes, gene amplification and deletion, tissue type and transcriptional data. Analysis of GDSC data is through a web portal focused on identifying molecular biomarkers of drug sensitivity based on queries of specific anticancer drugs or cancer genes. Graphical representations of the data are used throughout with links to related resources and all datasets are fully downloadable. GDSC provides a unique resource incorporating large drug sensitivity and genomic datasets to facilitate the discovery of new therapeutic biomarkers for cancer therapies.

Hali tarjima qilinmagan

Identifikatorlar

DOI: 10.1093/nar/gks1111

Iqtiboslar va manbalar

2 ta iqtibos0 ta foydalanilgan manba